vs
Side-by-side financial comparison of Natural Grocers by Vitamin Cottage, Inc. (NGVC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Natural Grocers by Vitamin Cottage, Inc. is the larger business by last-quarter revenue ($335.6M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). Natural Grocers by Vitamin Cottage, Inc. runs the higher net margin — 3.4% vs 1.6%, a 1.7% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 1.6%). Over the past eight quarters, Natural Grocers by Vitamin Cottage, Inc.'s revenue compounded faster (4.4% CAGR vs -0.2%).
Natural Grocers by Vitamin Cottage, Inc. is a U.S.-based specialty retail chain that offers certified organic groceries, dietary supplements, natural personal care items, and eco-friendly household products. It serves health-conscious consumers across multiple U.S. states, following strict quality standards that exclude artificial preservatives, colors, flavors and harmful additives.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NGVC vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $335.6M | $177.4M |
| Net Profit | $11.3M | $2.9M |
| Gross Margin | 29.5% | — |
| Operating Margin | 4.4% | 3.9% |
| Net Margin | 3.4% | 1.6% |
| Revenue YoY | 1.6% | 5.0% |
| Net Profit YoY | 14.0% | — |
| EPS (diluted) | $0.49 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $335.6M | $196.9M | ||
| Q3 25 | $336.1M | $179.5M | ||
| Q2 25 | $328.7M | $181.1M | ||
| Q1 25 | $335.8M | $168.9M | ||
| Q4 24 | $330.2M | $187.3M | ||
| Q3 24 | $322.7M | $168.6M | ||
| Q2 24 | $309.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $11.3M | — | ||
| Q3 25 | $11.8M | $5.4M | ||
| Q2 25 | $11.6M | $-4.8M | ||
| Q1 25 | $13.1M | $4.8M | ||
| Q4 24 | $9.9M | — | ||
| Q3 24 | $9.0M | $-143.5M | ||
| Q2 24 | $9.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 29.5% | 79.5% | ||
| Q3 25 | 29.5% | 80.9% | ||
| Q2 25 | 29.9% | 77.4% | ||
| Q1 25 | 30.3% | 79.7% | ||
| Q4 24 | 29.9% | 78.7% | ||
| Q3 24 | 29.6% | 76.9% | ||
| Q2 24 | 29.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 4.4% | 1.2% | ||
| Q3 25 | 4.6% | 3.5% | ||
| Q2 25 | 4.7% | 4.7% | ||
| Q1 25 | 5.2% | 1.2% | ||
| Q4 24 | 4.0% | 13.2% | ||
| Q3 24 | 3.7% | -82.8% | ||
| Q2 24 | 4.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.5% | 3.0% | ||
| Q2 25 | 3.5% | -2.7% | ||
| Q1 25 | 3.9% | 2.8% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 2.8% | -85.1% | ||
| Q2 24 | 3.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.49 | $0.05 | ||
| Q3 25 | $0.51 | $0.12 | ||
| Q2 25 | $0.50 | $-0.11 | ||
| Q1 25 | $0.56 | $0.10 | ||
| Q4 24 | $0.43 | $0.38 | ||
| Q3 24 | $0.38 | $-3.11 | ||
| Q2 24 | $0.40 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.2M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $220.0M | $653.9M |
| Total Assets | $668.6M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $23.2M | $238.4M | ||
| Q3 25 | $17.1M | $246.3M | ||
| Q2 25 | $13.2M | $445.9M | ||
| Q1 25 | $21.2M | $493.6M | ||
| Q4 24 | $6.3M | $484.6M | ||
| Q3 24 | $8.9M | $453.8M | ||
| Q2 24 | $13.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $220.0M | $693.1M | ||
| Q3 25 | $212.4M | $727.2M | ||
| Q2 25 | $202.5M | $757.8M | ||
| Q1 25 | $193.0M | $798.5M | ||
| Q4 24 | $181.9M | $778.3M | ||
| Q3 24 | $174.3M | $749.6M | ||
| Q2 24 | $167.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $668.6M | $1.3B | ||
| Q3 25 | $670.5M | $1.3B | ||
| Q2 25 | $659.0M | $1.5B | ||
| Q1 25 | $664.6M | $1.6B | ||
| Q4 24 | $648.9M | $1.6B | ||
| Q3 24 | $655.5M | $1.5B | ||
| Q2 24 | $654.4M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.1M | — |
| Free Cash FlowOCF − Capex | $11.6M | — |
| FCF MarginFCF / Revenue | 3.4% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | 1.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | $42.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $21.1M | $43.7M | ||
| Q3 25 | $15.6M | $60.8M | ||
| Q2 25 | $2.9M | $12.0M | ||
| Q1 25 | $34.1M | $35.5M | ||
| Q4 24 | $2.7M | $33.1M | ||
| Q3 24 | $24.5M | $53.9M | ||
| Q2 24 | $12.4M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $11.6M | $43.5M | ||
| Q3 25 | $7.5M | $57.0M | ||
| Q2 25 | $-4.2M | $9.3M | ||
| Q1 25 | $27.6M | $26.9M | ||
| Q4 24 | $-6.9M | $31.0M | ||
| Q3 24 | $18.0M | $49.8M | ||
| Q2 24 | $3.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 22.1% | ||
| Q3 25 | 2.2% | 31.7% | ||
| Q2 25 | -1.3% | 5.1% | ||
| Q1 25 | 8.2% | 15.9% | ||
| Q4 24 | -2.1% | 16.6% | ||
| Q3 24 | 5.6% | 29.6% | ||
| Q2 24 | 1.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 0.1% | ||
| Q3 25 | 2.4% | 2.2% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 1.9% | 5.1% | ||
| Q4 24 | 2.9% | 1.1% | ||
| Q3 24 | 2.0% | 2.4% | ||
| Q2 24 | 2.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.86× | — | ||
| Q3 25 | 1.32× | 11.20× | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 2.60× | 7.37× | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | 2.72× | — | ||
| Q2 24 | 1.35× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NGVC
| Grocery | $243.8M | 73% |
| Dietary Supplements | $60.7M | 18% |
| Manufactured Product Other | $31.0M | 9% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
